Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818269 | 0.94 | AHR (0.43) | LMNATSHRSMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL28370253 | 0.94 | AHR (0.43) | LMNATSHRSMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL10261885 | 0.94 | LTA4H (0.47) | LMNAHTTACACBLTA4HPLK1 | |
| SCHEMBL15947095 | 0.89 | ACACB (0.44) | LMNAHTTSMN1; SMN2ACACBLTA4H | |
| SCHEMBL1815976 | 0.88 | CYP3A4 (0.49) | LMNATSHRSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15490909 | 0.88 | ACACB (0.43) | LMNAHTTACACBLTA4HPLK1 | |
| SCHEMBL22113474 | 0.88 | ALDH1A1 (0.47) | TSHRSMN1; SMN2LTA4HPLK1ALDH1A1 | |
| SCHEMBL10262594 | 0.87 | LTA4H (0.47) | LMNATSHRSMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL22005275 | 0.87 | CYP3A4 (0.41) | LMNATSHRSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL17925375 | 0.87 | MAPT (0.50) | LMNAHTTSMN1; SMN2ACACBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916071-B2 | Chromene compound and curable composition | TOKUYAMA CORPORATION (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140225050-A1 | CHROMENE COMPOUND AND CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140225050-A1 | CHROMENE COMPOUND AND CURABLE COMPOSITION | CRY2, CRY1, CDYL | LMNA 1960/4885HTT 1210/4885TSHR 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.